P-89 ADHERENCE TO IMMUNOSUPPRESSIVE THERAPY IN LIVER TRANSPLANT PATIENTS: FACTORS ASSOCIATED TO COMPLIANCE AND IMPACT ON QUALITY OF LIFE

Conflict of interest: No Introduction and Objectives: One of the primary challenges following liver transplantation is preventing graft rejection, for which immunosuppressive therapy is essential. The success of this therapy depends, among other factors, on patient adherence to the prescribed medica...

Full description

Saved in:
Bibliographic Details
Main Authors: Carol Roa, Daniela Simian, Matías Martínez, Vicente Arancibia, Jaime Poniachik
Format: Article
Language:English
Published: Elsevier 2024-12-01
Series:Annals of Hepatology
Online Access:http://www.sciencedirect.com/science/article/pii/S1665268124004861
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850168362821222400
author Carol Roa
Daniela Simian
Matías Martínez
Vicente Arancibia
Jaime Poniachik
author_facet Carol Roa
Daniela Simian
Matías Martínez
Vicente Arancibia
Jaime Poniachik
author_sort Carol Roa
collection DOAJ
description Conflict of interest: No Introduction and Objectives: One of the primary challenges following liver transplantation is preventing graft rejection, for which immunosuppressive therapy is essential. The success of this therapy depends, among other factors, on patient adherence to the prescribed medication regimen. The aim was to evaluate adherence to immunosuppressive therapy and the possible factors associated to adherence in liver transplant patients. Patients / Materials and Methods: This is an analytical, observational, cross-sectional study conducted with liver transplant patients between 2004 and 2023 at Hospital Clínico Universidad de Chile. Participants were required to complete two self-administered questionnaires: the ''Simplified Medication Adherence Questionnaire'' (SMAQ) to assess adherence (classified as adherent or non-adherent) and the ''European Quality of Life-5 Dimensions'' (EQ-5D) to assess quality of life. Additionally, a form was used to collect sociodemographic and clinical data, supplemented with information from the hospital's medical records. All data were recorded using the REDCap® platform. Results and Discussion: The study included 29 patients with a median post-transplant follow-up of 37 months (range: 1 – 237 months). Of these patients, 41% (12 patients) were identified as non-adherent to immunosuppressive therapy, with occasional forgetfulness being the primary cause. Analysis revealed that younger patients, those with less comorbidity, and those with a longer time since transplantation were less adherent to the therapy. Tacrolimus was the most commonly used drug, and no significant differences in adherence were found based on the type of immunosuppressant used. Adherent patients reported a better quality of life compared to non-adherent patients. Conclusions: A significant proportion of liver transplant patients exhibit non-adherence to immunosuppressive therapy. Factors such as medication forgetfulness, time since transplantation, and the presence of chronic illnesses impact adherence. It is recommended to enhance patient-provider relationships, regularly assess adherence, and provide patient education to improve quality of life and minimize the risk of graft rejection.
format Article
id doaj-art-3c293d725f8d4688a48830fc0d350779
institution OA Journals
issn 1665-2681
language English
publishDate 2024-12-01
publisher Elsevier
record_format Article
series Annals of Hepatology
spelling doaj-art-3c293d725f8d4688a48830fc0d3507792025-08-20T02:20:58ZengElsevierAnnals of Hepatology1665-26812024-12-012910170310.1016/j.aohep.2024.101703P-89 ADHERENCE TO IMMUNOSUPPRESSIVE THERAPY IN LIVER TRANSPLANT PATIENTS: FACTORS ASSOCIATED TO COMPLIANCE AND IMPACT ON QUALITY OF LIFECarol Roa0Daniela Simian1Matías Martínez2Vicente Arancibia3Jaime Poniachik4Departamento de Ciencias y Tecnología Farmacéuticas, Facultad de Ciencias Químicas y Farmacéuticas, Universidad de Chile, Santiago, ChileHospital Clínico Universidad de Chile, Santiago, ChileDepartamento de Ciencias y Tecnología Farmacéuticas, Facultad de Ciencias Químicas y Farmacéuticas, Universidad de Chile, Santiago, ChileDepartamento de Ciencias y Tecnología Farmacéuticas, Facultad de Ciencias Químicas y Farmacéuticas, Universidad de Chile, Santiago, ChileHospital Clínico Universidad de Chile, Santiago, ChileConflict of interest: No Introduction and Objectives: One of the primary challenges following liver transplantation is preventing graft rejection, for which immunosuppressive therapy is essential. The success of this therapy depends, among other factors, on patient adherence to the prescribed medication regimen. The aim was to evaluate adherence to immunosuppressive therapy and the possible factors associated to adherence in liver transplant patients. Patients / Materials and Methods: This is an analytical, observational, cross-sectional study conducted with liver transplant patients between 2004 and 2023 at Hospital Clínico Universidad de Chile. Participants were required to complete two self-administered questionnaires: the ''Simplified Medication Adherence Questionnaire'' (SMAQ) to assess adherence (classified as adherent or non-adherent) and the ''European Quality of Life-5 Dimensions'' (EQ-5D) to assess quality of life. Additionally, a form was used to collect sociodemographic and clinical data, supplemented with information from the hospital's medical records. All data were recorded using the REDCap® platform. Results and Discussion: The study included 29 patients with a median post-transplant follow-up of 37 months (range: 1 – 237 months). Of these patients, 41% (12 patients) were identified as non-adherent to immunosuppressive therapy, with occasional forgetfulness being the primary cause. Analysis revealed that younger patients, those with less comorbidity, and those with a longer time since transplantation were less adherent to the therapy. Tacrolimus was the most commonly used drug, and no significant differences in adherence were found based on the type of immunosuppressant used. Adherent patients reported a better quality of life compared to non-adherent patients. Conclusions: A significant proportion of liver transplant patients exhibit non-adherence to immunosuppressive therapy. Factors such as medication forgetfulness, time since transplantation, and the presence of chronic illnesses impact adherence. It is recommended to enhance patient-provider relationships, regularly assess adherence, and provide patient education to improve quality of life and minimize the risk of graft rejection.http://www.sciencedirect.com/science/article/pii/S1665268124004861
spellingShingle Carol Roa
Daniela Simian
Matías Martínez
Vicente Arancibia
Jaime Poniachik
P-89 ADHERENCE TO IMMUNOSUPPRESSIVE THERAPY IN LIVER TRANSPLANT PATIENTS: FACTORS ASSOCIATED TO COMPLIANCE AND IMPACT ON QUALITY OF LIFE
Annals of Hepatology
title P-89 ADHERENCE TO IMMUNOSUPPRESSIVE THERAPY IN LIVER TRANSPLANT PATIENTS: FACTORS ASSOCIATED TO COMPLIANCE AND IMPACT ON QUALITY OF LIFE
title_full P-89 ADHERENCE TO IMMUNOSUPPRESSIVE THERAPY IN LIVER TRANSPLANT PATIENTS: FACTORS ASSOCIATED TO COMPLIANCE AND IMPACT ON QUALITY OF LIFE
title_fullStr P-89 ADHERENCE TO IMMUNOSUPPRESSIVE THERAPY IN LIVER TRANSPLANT PATIENTS: FACTORS ASSOCIATED TO COMPLIANCE AND IMPACT ON QUALITY OF LIFE
title_full_unstemmed P-89 ADHERENCE TO IMMUNOSUPPRESSIVE THERAPY IN LIVER TRANSPLANT PATIENTS: FACTORS ASSOCIATED TO COMPLIANCE AND IMPACT ON QUALITY OF LIFE
title_short P-89 ADHERENCE TO IMMUNOSUPPRESSIVE THERAPY IN LIVER TRANSPLANT PATIENTS: FACTORS ASSOCIATED TO COMPLIANCE AND IMPACT ON QUALITY OF LIFE
title_sort p 89 adherence to immunosuppressive therapy in liver transplant patients factors associated to compliance and impact on quality of life
url http://www.sciencedirect.com/science/article/pii/S1665268124004861
work_keys_str_mv AT carolroa p89adherencetoimmunosuppressivetherapyinlivertransplantpatientsfactorsassociatedtocomplianceandimpactonqualityoflife
AT danielasimian p89adherencetoimmunosuppressivetherapyinlivertransplantpatientsfactorsassociatedtocomplianceandimpactonqualityoflife
AT matiasmartinez p89adherencetoimmunosuppressivetherapyinlivertransplantpatientsfactorsassociatedtocomplianceandimpactonqualityoflife
AT vicentearancibia p89adherencetoimmunosuppressivetherapyinlivertransplantpatientsfactorsassociatedtocomplianceandimpactonqualityoflife
AT jaimeponiachik p89adherencetoimmunosuppressivetherapyinlivertransplantpatientsfactorsassociatedtocomplianceandimpactonqualityoflife